Alpha-GPC vs. Citicoline: Which Choline Source Is Best for Brain Health?
Both alpha-GPC and citicoline (also known as CDP-choline) are popular supplemental choline sources, and both can cross the blood-brain barrier to support acetylcholine production. But they are not the same molecule, and the differences between them matter more than most supplement comparisons suggest.
This article examines what the research actually says about each compound: how they work, what evidence supports their use, what the safety data show, and which situations each one may be better suited for. We'll be transparent about where the evidence is strong and where it's still catching up to the marketing.
Alpha-GPC vs. Citicoline · At a Glance
What They Share
Both deliver choline to the brain and support acetylcholine synthesis
Both are well-absorbed orally and cross the blood-brain barrier
Key Difference
Alpha-GPC delivers choline + glycerophosphate; citicoline delivers choline + cytidine (which converts to uridine)
The non-choline half of each molecule drives their distinct effects
Safety Signal
A large cohort study found alpha-GPC associated with increased stroke risk, possibly via TMAO production
Citicoline has not shown this signal in comparable research
Best For
Alpha-GPC: acute cognitive tasks, possibly exercise performance
Citicoline: daily cognitive support, long-term neuroprotection, multi-neurotransmitter support
Table of Contents
Why Choline Matters for Your Brain
Choline is an essential nutrient that your body needs but cannot produce in sufficient quantities on its own. The brain uses it for two critical functions: building the neurotransmitter acetylcholine (which drives memory, attention, and learning) and maintaining the structural integrity of neuronal cell membranes through phospholipid synthesis.
Despite its importance, most people don't consume enough. The adequate intake is 550 mg/day for men and 425 mg/day for women, yet population surveys consistently show that the majority of adults fall short. Rich dietary sources include egg yolks, liver, and beef, but even with a varied diet, hitting the target is surprisingly difficult.
This is where supplemental choline sources enter the picture. Dietary choline (mostly as phosphatidylcholine) must be broken down and reassembled before it's useful to the brain. Supplemental forms like alpha-GPC and citicoline are designed to be more efficiently delivered to the central nervous system. But "more efficient" does not mean "identical." These two compounds take meaningfully different paths once absorbed, and understanding those paths is the key to choosing between them.
Analogy
Think of choline as a building material your brain needs constantly. Dietary choline is like raw lumber that needs to be milled and shaped before use. Alpha-GPC and citicoline are more like pre-cut components, each designed for a slightly different part of the structure. Both deliver the wood, but each comes with different hardware attached.
Choline is essential for acetylcholine production and cell membrane maintenance. Most adults don't get enough from diet alone. Supplemental forms are designed for more efficient brain delivery, but alpha-GPC and citicoline differ in important ways beyond their shared choline content.
Alpha-GPC: What the Evidence Shows
Alpha-GPC (L-alpha-glycerylphosphorylcholine) is a naturally occurring choline compound found in small amounts in the brain. As a supplement, it delivers choline bound to a glycerophosphate backbone. Once absorbed, it releases free choline that can be used for acetylcholine synthesis, along with glycerophosphate that contributes to cell membrane phospholipid production.
Alpha-GPC contains roughly 40% choline by weight, making it one of the most concentrated supplemental choline sources available. This high choline density is often cited as a primary advantage, particularly for people seeking to raise acetylcholine levels efficiently.
Cognitive Effects
The cognitive research on alpha-GPC falls into two broad categories: studies in populations with existing cognitive impairment, and studies in healthy adults.
In populations with cognitive decline, a 2023 meta-analysis found that alpha-GPC, both alone and in combination with the Alzheimer's drug donepezil, improved cognition, functional outcomes, and behavioral measures in patients with cerebrovascular-related cognitive impairment. However, the authors noted that the included studies had significant methodological limitations.
Key Study
Who: Meta-analysis of 7 RCTs and 1 cohort study in patients with adult-onset cognitive impairment
Dose: Varied across studies; most used 400 mg three times daily
Measured: Cognition (MMSE, ADAS-cog), functional outcomes, behavioral measures
Findings: Alpha-GPC alone or with donepezil significantly improved cognition (MD: 3.50, 95% CI: 0.36 to 6.63) and behavioral outcomes vs. placebo or other medications
Limitations: High risk of bias in included studies; most participants had cerebrovascular-related cognitive impairment specifically; limited generalizability to healthy populations
Sagaro et al., 2023 · PubMed
In healthy adults, the evidence is more limited but encouraging. A 2024 randomized, double-blind, crossover trial in 20 young, resistance-trained men found that a single dose of alpha-GPC (630 mg or 315 mg) significantly improved cognitive performance on the Stroop test compared to placebo 60 minutes after ingestion. The higher dose also produced faster completion times.
Key Study
Who: 20 healthy, resistance-trained males (mean age 31.3 years)
Dose: Single acute dose of 630 mg or 315 mg alpha-GPC
Measured: Stroop test, N-Back, Flanker task, vertical jump, bench press throw, growth hormone
Findings: Both doses significantly improved Stroop total score vs. placebo (p = 0.013 for 630 mg; p = 0.046 for 315 mg). No significant differences for N-Back or Flanker tests. No effect on growth hormone or physical performance.
Limitations: Very small sample (n=20); only young, fit men; single acute dose design; no long-term data; funded by a supplement company
Kerksick, 2024 · PubMed
The Growth Hormone Claim
Alpha-GPC is frequently marketed as a growth hormone booster, particularly in fitness contexts. The evidence here deserves careful scrutiny. The 2024 Kerksick study specifically measured growth hormone after alpha-GPC supplementation followed by resistance exercise and found no significant differences between alpha-GPC and placebo. Earlier studies that reported growth hormone effects used different protocols and often had very small sample sizes. At present, the growth hormone claim is not well-supported by controlled research.
Alpha-GPC may support acute cognitive performance and has shown benefits in populations with existing cognitive impairment, particularly alongside standard medications. However, the evidence in healthy adults is limited to small, short-term studies, and the commonly marketed growth hormone benefit was not confirmed in the most recent controlled trial.
Citicoline: What the Evidence Shows
Citicoline (also known as CDP-choline) is a naturally occurring intermediate in the body's phospholipid synthesis pathway. When you take it orally, it is rapidly broken down in the gut into two components: choline and cytidine. The choline follows the same path as alpha-GPC's choline, supporting acetylcholine production. But the cytidine takes a different and important route: it is converted to uridine, a nucleoside that plays a role in neuronal membrane repair, synapse formation, and RNA synthesis.
This dual-action profile means citicoline does more than just supply choline. The uridine pathway supports the synthesis of phosphatidylcholine through a separate mechanism (the Kennedy pathway), and research suggests citicoline may also influence dopamine and norepinephrine levels in the central nervous system.
Cognitive Effects
Citicoline has a substantially larger evidence base than alpha-GPC. A comprehensive 2006 pharmacological review documented that citicoline increases norepinephrine and dopamine levels in the CNS, has neuroprotective effects in ischemic and hypoxic conditions, and improves learning and memory in animal models of brain aging.
In clinical settings, a 2023 meta-analysis of studies in patients with mild cognitive impairment, Alzheimer's disease, and post-stroke dementia found that citicoline improved cognitive status across all included studies, with pooled standardized mean differences ranging from 0.56 to 1.57 depending on the sensitivity analysis.
Key Study
Who: Meta-analysis of 7 studies in patients with MCI, Alzheimer's disease, or post-stroke dementia (2010-2022)
Dose: Varied across studies; commonly 500-2,000 mg/day
Measured: Cognitive function across multiple standardized scales
Findings: All studies showed positive effects on cognition. Pooled SMD ranged from 0.56 (95% CI: 0.37-0.75) to 1.57 (95% CI: 0.77-2.37)
Limitations: Overall study quality rated as poor; significant risk of bias in favor of the intervention; heterogeneous patient populations and dosing protocols
Bonvicini et al., 2023 · PubMed
In healthy adults, a 2020 systematic review concluded that citicoline enhances cognitive functions and improves prognosis after stroke, noting its positive impact on learning and cognitive function even in healthy populations. A 2014 RCT of a citicoline-caffeine beverage in 60 healthy adults found significantly faster reaction times, fewer errors in go/no-go tasks, and improved sustained attention compared to placebo, though the combination with caffeine makes it difficult to attribute effects to citicoline alone.
Beyond Acetylcholine: The Multi-Neurotransmitter Profile
One of citicoline's distinguishing features is its documented influence on neurotransmitters beyond acetylcholine. The Secades and Lorenzo review (2006) reported that citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS. This is mechanistically plausible given citicoline's role in phospholipid membrane synthesis, which affects the function of neurotransmitter receptors and transporters embedded in those membranes.
This multi-pathway activity may be particularly relevant for people seeking broad cognitive support rather than a narrow boost in one neurotransmitter system. However, it's important to note that most of the dopamine and norepinephrine data come from animal studies and mechanistic research, not large human trials specifically measuring these neurotransmitters.
Analogy
If alpha-GPC is like delivering a concentrated fuel injection to one engine (acetylcholine), citicoline is more like servicing the entire vehicle. It supplies fuel (choline for acetylcholine), performs structural maintenance (uridine for membrane repair), and tunes multiple systems (dopamine and norepinephrine pathways). The trade-off is that the effects may be less immediately noticeable but potentially more comprehensive over time.
Citicoline has a broader evidence base than alpha-GPC, with documented effects on cognitive function in both impaired and healthy populations. Its unique delivery of cytidine (converted to uridine) supports neuronal membrane repair and phospholipid synthesis through a pathway that alpha-GPC does not share. Evidence also suggests effects on dopamine and norepinephrine, though primarily from preclinical research.
Head-to-Head: How They Compare
Direct comparison studies between alpha-GPC and citicoline are rare, which means most head-to-head assessments rely on comparing separate bodies of research. This is an important caveat: when two compounds haven't been tested against each other in the same trial, any comparison has inherent limitations.
That said, the available evidence does reveal meaningful differences across several dimensions:
Choline Delivery
Alpha-GPC is approximately 40% choline by weight, while citicoline is roughly 18%. On paper, this means alpha-GPC delivers more free choline per milligram. In practice, this difference matters most if your primary goal is maximizing acetylcholine production as quickly as possible. If you're also interested in the non-choline benefits (uridine, membrane repair, multi-neurotransmitter support), citicoline's lower choline density is a feature, not a limitation, because that molecular weight is carrying cytidine instead.
Mechanism Breadth
Alpha-GPC's primary documented mechanism is straightforward: deliver choline for acetylcholine synthesis and glycerophosphate for membrane phospholipids. Citicoline acts through additional pathways: the cytidine-to-uridine conversion supports Kennedy pathway phospholipid synthesis, and the compound has documented effects on dopamine and norepinephrine systems. The breadth of citicoline's mechanism is better documented in the literature, though this also reflects the fact that citicoline has simply been studied more extensively.
Research Volume and Quality
Citicoline has a substantially larger body of clinical research. A 2020 systematic review identified 47 articles on citicoline in neurological disorders alone. Alpha-GPC's clinical literature is smaller, and its most rigorous cognitive trial in healthy adults (Kerksick, 2024) included only 20 participants. Both compounds suffer from a common problem in supplement research: many studies have small sample sizes, short durations, and potential conflicts of interest.
Onset and Duration
Alpha-GPC is often described as "fast-acting," and there is some support for this: the Kerksick study showed cognitive effects 60 minutes after a single dose. Citicoline's benefits appear to build more gradually, with most positive clinical trials using daily dosing over weeks to months. This distinction suggests alpha-GPC may be better suited for acute cognitive demands, while citicoline may offer more for sustained, daily use.
Alpha-GPC delivers more concentrated choline and may offer faster acute effects. Citicoline provides broader mechanistic support through its uridine pathway and multi-neurotransmitter activity, backed by a larger evidence base. Neither compound has been clearly proven superior to the other in direct comparison trials.
The Safety Question: TMAO and Cardiovascular Risk
Both alpha-GPC and citicoline are generally considered well-tolerated, and common side effects for both are mild: occasional headache, digestive discomfort, and insomnia at higher doses. But there is one safety signal that separates the two compounds, and it warrants serious attention.
Alpha-GPC and the TMAO Pathway
When choline-containing compounds reach the gut, bacteria can convert some of the choline into trimethylamine (TMA), which the liver then oxidizes into trimethylamine N-oxide (TMAO). Elevated TMAO has been associated with increased cardiovascular risk, including atherosclerosis and stroke, in a growing body of research.
Alpha-GPC's structure makes it particularly susceptible to this conversion because it releases a high proportion of free choline that is accessible to gut bacteria. A 2021 study from the Cleveland Clinic found that alpha-GPC promoted atherosclerosis in hyperlipidemic mice through TMAO-mediated mechanisms, shifted gut microbial communities, and activated inflammatory signaling pathways.
Key Study
Who: Hyperlipidemic (ApoE-knockout) mice
Dose: Alpha-GPC supplementation (preclinical dosing)
Measured: Atherosclerosis progression, TMAO levels, gut microbiome composition, inflammatory markers
Findings: Alpha-GPC promoted atherosclerosis, was metabolized to TMAO, shifted gut microbiome composition, increased pro-inflammatory signaling (NF-kB and MAPK pathways)
Limitations: Animal study using a hyperlipidemic mouse model; dosing may not directly translate to typical human supplementation; short duration
Wang et al., 2021 · PubMed
More concerning is the human epidemiological data. A large population-based cohort study using the South Korean National Health Insurance Service database followed over 12 million individuals aged 50 and older for 10 years. After adjusting for traditional cerebrovascular risk factors, alpha-GPC users showed a significantly higher risk of total stroke (adjusted hazard ratio: 1.43), ischemic stroke (aHR: 1.34), and hemorrhagic stroke (aHR: 1.37) compared to non-users. The association showed a dose-response pattern, with longer duration of use linked to higher risk.
Key Study
Who: 12,008,977 individuals aged 50+ from the South Korean NHIS database
Dose: Prescribed alpha-GPC, categorized by duration of use
Measured: 10-year incidence of total, ischemic, and hemorrhagic stroke
Findings: Alpha-GPC users had significantly higher stroke risk (aHR: 1.43, 95% CI: 1.41-1.46 in matched cohort). Risk increased in a dose-response manner with duration of use.
Limitations: Observational design (cannot prove causation); alpha-GPC users were older and may have had pre-existing cognitive concerns; confounding by indication is possible; conducted in a population where alpha-GPC is prescribed as a medication, not taken as a supplement
Lee et al., 2021 · PubMed
Why Citicoline May Avoid This Problem
Citicoline's molecular structure provides a potential explanation for why it has not shown the same TMAO signal. When citicoline is absorbed, it is hydrolyzed into choline and cytidine. The choline released from citicoline is phosphorylated (still bound to a phosphate group), which reduces the proportion of free choline available to gut bacteria for TMA conversion. In contrast, alpha-GPC releases a larger proportion of unbound choline that is more accessible to microbial metabolism.
No comparable cohort study has identified a stroke risk association with citicoline use, and its long clinical history (it has been used in stroke rehabilitation research for decades) has not produced cardiovascular safety signals. The Secades and Lorenzo review (2006) specifically noted that citicoline causes no significant systemic cholinergic effects and is well-tolerated.
However, honesty requires acknowledging that citicoline has not been subjected to the same type of large-scale, long-term population study that flagged alpha-GPC's risk. The absence of evidence is not the same as evidence of absence. Citicoline's safety profile looks favorable, but it has not been tested in the same way.
A large observational study found alpha-GPC associated with significantly elevated stroke risk over 10 years, with a dose-response relationship. Animal research has identified TMAO production as a plausible mechanism. Citicoline has not shown this signal, possibly because its molecular structure limits free choline exposure to gut bacteria. However, the same type of large-scale long-term safety study has not been conducted for citicoline.
Choosing Between Them
No single choline source is universally "best." The right choice depends on what you're trying to achieve, how long you plan to supplement, and your individual health profile.
Alpha-GPC May Be Better Suited For:
- Short-term or acute cognitive demands where rapid choline delivery is the priority
- Situations where you need the highest choline concentration per dose
- Use alongside other cognitive support strategies for occasional, not daily, supplementation
If you choose alpha-GPC, be aware of the TMAO concern. Consider keeping doses moderate, avoiding long-term daily use unless under medical guidance, and discussing cardiovascular risk factors with your healthcare provider.
Citicoline May Be Better Suited For:
- Daily, long-term cognitive support where consistent neuroprotection is the goal
- People interested in broad neurotransmitter support beyond acetylcholine alone
- Those who want the additional benefits of the uridine pathway (membrane repair, synapse formation)
- Anyone with cardiovascular risk factors who wants to minimize TMAO exposure
A Note on Labeling
If you do choose alpha-GPC, pay careful attention to product labels. Many supplements list alpha-GPC at 50% concentration (meaning half the capsule weight is alpha-GPC and half is a carrier). A "600 mg alpha-GPC" capsule at 50% concentration actually delivers 300 mg of alpha-GPC, and therefore roughly 120 mg of actual choline. This discrepancy is common and rarely explained clearly on labels.
Why We Chose Citicoline for eudopa
When formulating eudopa, we chose citicoline as our choline source. The decision came down to three factors: the broader mechanistic profile (choline plus uridine pathway support, with documented effects on dopamine and norepinephrine), the stronger long-term safety data, and the larger clinical evidence base. For a daily-use supplement designed to support sustained cognitive function, these advantages aligned with what we believe the evidence best supports.
That said, alpha-GPC is a legitimate compound with real research behind it. We chose citicoline because it better fits the long-term, multi-pathway approach that guides our formulations, not because alpha-GPC is without merit.
The choice between alpha-GPC and citicoline depends on your goals and timeline. For acute, short-term choline delivery, alpha-GPC has shown promise. For daily cognitive support with a broader safety and mechanistic profile, citicoline has more evidence in its favor. Both deserve honest assessment, not marketing spin.
Frequently Asked Questions
Can I take alpha-GPC and citicoline together?
There's no published research on combining the two. Since both supply choline, stacking them would increase your total choline intake and potentially increase TMAO production from the alpha-GPC component. If you're considering combining them, consult your healthcare provider to discuss appropriate dosing and monitor for any adverse effects.
How much choline do I actually get from each supplement?
Alpha-GPC is approximately 40% choline by weight (so 600 mg alpha-GPC delivers roughly 240 mg choline). Citicoline is approximately 18% choline by weight (so 500 mg citicoline delivers roughly 90 mg choline). However, citicoline's value isn't measured by choline content alone, since the cytidine component provides independent neurological benefits.
Is the stroke risk from alpha-GPC proven?
Not definitively. The Lee et al. (2021) study was observational, meaning it identified an association but could not prove causation. People who were prescribed alpha-GPC may have already had underlying neurological concerns that predisposed them to stroke (confounding by indication). However, the dose-response relationship and the plausible TMAO mechanism make this a signal worth taking seriously, not dismissing.
Does citicoline really boost dopamine?
Preclinical research and pharmacological reviews have documented that citicoline increases dopamine and norepinephrine levels in the CNS. However, this evidence comes primarily from animal studies and mechanistic research, not from large human trials specifically measuring brain dopamine levels. The effect is plausible and supported by the science, but "boost" may overstate the certainty of what happens at typical supplement doses in humans.
How long does it take for citicoline to work?
Most positive clinical trials used daily dosing over 4 to 12 weeks before measuring outcomes. Some studies of citicoline in healthy adults showed effects on attention within a few weeks. Unlike alpha-GPC, which has shown acute effects within 60 minutes of a single dose, citicoline's benefits appear to build gradually with consistent use.
What's the typical dosage for each?
Research on alpha-GPC has commonly used 400 mg taken two to three times daily (800-1,200 mg/day) in clinical populations, and 300-600 mg in acute studies in healthy adults. Research on citicoline has commonly used 250-1,000 mg/day, with 500 mg/day being a frequently studied dose. These ranges are based on study protocols, not official guidelines. Always consult your healthcare provider for personalized dosing advice.
Are there people who should avoid either supplement?
Given the TMAO safety signal, individuals with existing cardiovascular disease, stroke history, or elevated cardiovascular risk factors should discuss alpha-GPC use with their doctor before supplementing. Both compounds should be used cautiously by anyone taking cholinergic medications (such as acetylcholinesterase inhibitors) due to potential additive effects. Pregnant and breastfeeding women should consult their healthcare provider before using either supplement.
References
- Lee, G., Choi, S., Chang, J., et al. "Association of L-alpha Glycerylphosphorylcholine With Subsequent Stroke Risk After 10 Years." JAMA Network Open, vol. 4, no. 11, e2136008, 2021. PubMed
- Wang, Z., Hazen, J., Jia, X., et al. "The Nutritional Supplement L-alpha Glycerylphosphorylcholine Promotes Atherosclerosis." International Journal of Molecular Sciences, vol. 22, no. 24, 13477, 2021. PubMed
- Sagaro, G.G., Traini, E., Amenta, F. "Activity of Choline Alphoscerate on Adult-Onset Cognitive Dysfunctions: A Systematic Review and Meta-Analysis." Journal of Alzheimer's Disease, vol. 92, no. 1, pp. 59-70, 2023. PubMed
- Kerksick, C.M. "Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men." Nutrients, vol. 16, no. 23, 4240, 2024. PubMed
- Bonvicini, M., Travaglini, S., Lelli, D., et al. "Is Citicoline Effective in Preventing and Slowing Down Dementia? A Systematic Review and a Meta-Analysis." Nutrients, vol. 15, no. 2, 386, 2023. PubMed
- Jasielski, P., Piedel, F., Piwek, M., et al. "Application of Citicoline in Neurological Disorders: A Systematic Review." Nutrients, vol. 12, no. 10, 3113, 2020. PubMed
- Secades, J.J. and Lorenzo, J.L. "Citicoline: Pharmacological and Clinical Review, 2006 Update." Methods and Findings in Experimental and Clinical Pharmacology, vol. 28 Suppl B, pp. 1-56, 2006. PubMed
- Bruce, S.E., Werner, K.B., Preston, B.F., et al. "Improvements in Concentration, Working Memory and Sustained Attention Following Consumption of a Natural Citicoline-Caffeine Beverage." International Journal of Food Sciences and Nutrition, vol. 65, no. 8, pp. 1003-7, 2014. PubMed
- Che, X., Zhao, Y., Xu, Z., et al. "Unlocking the Potential of L-alpha-Glycerylphosphorylcholine: From Metabolic Pathways to Therapeutic Applications." Nutrition Reviews, vol. 83, no. 8, pp. 1594-1620, 2025. PubMed
This article is for informational purposes only and does not constitute medical advice. The information presented here reflects the state of published research at the time of writing and may not capture all available evidence. Consult a qualified healthcare professional before starting any supplement regimen, especially if you have existing health conditions or take medications.
Applied brain science. Delivered weekly.
Weekly tips on brain science, habits, and supplements.
No spam. Unsubscribe anytime.
